aiqbench analysis
Warp Sciences is leveraging AI models trained on data from automated physical chemistry experiments to accelerate lead optimization for biotech clients. This approach addresses the specific need for real-world experimental data at scale, which is currently lacking in many scientific domains compared to software engineering. The startup aims to provide high-caliber U.S.-based contract research services that mitigate intellectual property risks associated with overseas partners.
Ex-OpenAI science chief Kevin Weil launches Warp Sciences with $215M for drug chemistry
Drug discovery chemistry startup Warp Sciences Inc. launched today with $215 million in new funding, six months after co-founder and Chief Executive Kevin Weil left his job running science initiatives at OpenAI Group PBC. Warp is building a chemistry contract research organization in the U.S. to supply biotech and pharmaceutical companies with the molecules their […] The post Ex-OpenAI science chief Kevin Weil launches Warp Sciences with $215M for drug chemistry appeared first on SiliconANGLE.
Drug discovery chemistry startup Warp Sciences Inc. launched today with $215 million in new funding, six months after co-founder and Chief Executive Kevin Weil left his job running science initiatives at OpenAI Group PBC. Warp is building a chemistry contract research organization in the U.S. to supply biotech and pharmaceutical companies with the molecules their drug programs need. Lead optimization analog…
Excerpt shown under the publisher's RSS terms · 61 words · full text and figures are on the publisher's site